Presentation and prognosis of shrinking lung syndrome in systemic lupus erythematosus: report of four cases

@article{Calderaro2011PresentationAP,
  title={Presentation and prognosis of shrinking lung syndrome in systemic lupus erythematosus: report of four cases},
  author={D{\'e}bora Cerqueira Calderaro and Gilda Aparecida Ferreira},
  journal={Rheumatology International},
  year={2011},
  volume={32},
  pages={1391-1396}
}
Systemic lupus erythematosus is an autoimmune systemic disease that commonly affects the respiratory system. Shrinking lung syndrome is a rare respiratory complication associated with systemic lupus erythematosus. Patients present with dyspnea alone or associated with chest pain and orthopnea, lung volume reduction with no parenchymal abnormalities and a restrictive ventilatory defect on pulmonary function tests. The pathogenesis, treatment, and prognosis of shrinking lung syndrome remain… 

Shrinking lung syndrome in systemic lupus erythematosus: a single-centre experience

TLDR
The characteristics of SLS in the lupus cohort with emphasis on prevalence, presentation, treatment and outcomes were described, and a chronic restrictive ventilatory defect usually persisted.

Shrinking Lung Syndrome in a Young Female: A Rare Pulmonary Manifestation of Systemic Lupus Erythematosus

TLDR
A case ofshrinking lung syndrome is presented in a young African American woman with a history of systemic lupus erythematosus who presents with shortness of breath and chest pain associated with breathing.

Shrinking lung syndrome treated with rituximab in pediatric systemic lupus erythematosus: a case report and review of the literature

TLDR
This is the second reported case of a child treated with rituximab for SLS who recovered normal lung function and is important to recognize SLS as a possible cause of dyspnea and chest pain in a child with SLE.

Shrinking Lung Syndrome in Systemic Lupus Erythematosus

TLDR
There are no standardized guidelines for the treatment of SLS in SLE, however, the majority of patients showed good response on medium to high doses of glucocorticoids and an immunosuppressive agent should be added if the patient fails to improve on steroids alone.

Shrinking lung syndrome in systemic lupus erythematosus

TLDR
The clinical features, investigation findings, approaches to management, and outcome in a case series of 9 adult patients with SLE and SLS diagnosed during a 35-year period in 3 referral tertiary care hospitals in Spain are analyzed.

Shrinking lung syndrome and systemic lupus erythematosus: a case series and literature review.

TLDR
Two previously unreported cases ofshrinking lung syndrome are provided, and the available literature on the pathophysiology, clinical features and management of SLS is reviewed.

Evaluating systemic lupus erythematosus patients for lung involvement

TLDR
Clinicians should consider evaluation for SLS among symptomatic patients with long-standing disease and a history of pleuritis when compared with symptomatic controls, as respiratory symptoms, abnormal lung function, and SLS are common in SLE.

Severe cognitive dysfunction and shrinking lung syndrome in systemic lupus erythematous

TLDR
The authors report the case of a 49-year-old woman whose first manifestation of SLE was represented by two rare manifestations: rapidly progressive cognitive impairment, which was associated with respiratory failure caused by the shrinking lung syndrome, and under-diagnosis of lupus pulmonary complications.

Severe hypoxemia without pulmonary infiltrates in systemic lupus erythematosus

TLDR
The article reviews the causes of severe hypoxemia in a SLE patient who had pulmonary hypertension,hypertension patent foramen ovale, a history of recreational drugs use, asthma, and possible antiphospholipid syndrome who presented with acute dyspnea and severe Hypoxemia.

References

SHOWING 1-10 OF 14 REFERENCES

Presentation and prognosis of the shrinking lung syndrome in systemic lupus erythematosus.

TLDR
The long-term prognosis of the SLS patients was reasonable, highlighting the importance of establishing a correct diagnosis and in particular differentiating it from fibrosing lung disease.

Shrinking lung syndrome in systemic lupus erythematosus and Sjogren's syndrome.

TLDR
The case of a 22-year-old man presenting with a 7-month history of dry mouth and dry eyes accompanied by increasing difficulty in breathing, progressing to dyspnea at rest is reported, with a diagnosis of SLE with secondary Sjogren's syndrome (SS) and SLS.

Shrinking lung syndrome as a presenting manifestation of systemic lupus erythematosus in a female Kuwaiti

TLDR
A 21-year-old female Kuwaiti who presented with SLS had dyspnea, respiratory muscle dysfunction, characteristic chest radiographic findings of small lung volumes, elevated right hemidiaphragm, and basilar atelectasis.

Association of the shrinking lung syndrome in systemic lupus erythematosus with pleurisy: a systematic review.

Shrinking lungs syndrome, a rare manifestation of systemic lupus erythematosus.

TLDR
The shrinking lungs syndrome (SLS), characterised by dyspnoea, diaphragmatic elevation and a restrictive pattern in the spirometry, is reported.

Bilateral phrenic paralysis in a patient with systemic lupus erythematosus.

TLDR
It is concluded that severe diaphragm palsy is possibly due to phrenic nerve lesions in SLE, and that the link between diaphRAGm dysfunction and the SLS is probably not a straightforward one.

Diaphragm function and lung involvement in systemic lupus erythematosus.

Diaphragm strength in the shrinking lung syndrome of systemic lupus erythematosus.

TLDR
The 'shrinking lung' syndrome of SLE is not explained by a primary abnormality of the diaphragm, and analysis of the 12-s maximum voluntary ventilation suggested a restriction in chest-wall expansion, although it was not possible to identify the underlying cause on the basis of results.

Síndrome do pulmão encolhido no lúpus eritematoso sistêmico

TLDR
A case that meets diagnostic criteria for systemic lupus erythematosus is reported, emphasizing the pathogenesis proposed, as well as the therapeutic options available.